



Zyflo CR[®] (zileuton) – First-time generic

- On March 27, 2017, Pack/Rising Pharmaceuticals launched an [AB-rated](#) generic version of Chiesi's [Zyflo CR \(zileuton\)](#) 600 mg extended-release tablets.
- Zyflo CR is approved for the prophylaxis and chronic treatment of asthma in adults and children 12 years of age and older.
 - Zyflo CR is not indicated for use in the reversal of bronchospasm in acute asthma attacks.
 - Zyflo CR can be continued during acute exacerbations of asthma.
- Zileuton is also available as the branded product [Zyflo[®]](#) and has the same indication as Zyflo CR.
 - Zyflo is available as 600 mg tablets. The recommended dose is 600 mg orally given 4 times daily.
 - The recommended dose of Zyflo CR is two, 600 mg extended-release tablets orally given twice daily.



OptumRx[®] specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum[®] company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews[®] is published by the OptumRx Clinical Services Department.

©2017 Optum, Inc. All rights reserved.